Disease Detail

ID DOID:3347
Name osteosarcoma
Definition A bone cancer that is located_in bone that has_material_basis_in cells of mesenchymal origin.
Source DiseaseOntology.org
Alt Ids DOID:183
Path disease disease of cellular proliferation cancer cell type cancer osteosarcoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 R280M Nutlin-3 osteosarcoma resistant detail...
TP53 I232S Nutlin-3 osteosarcoma resistant detail...
TP53 E258Q Nutlin-3 osteosarcoma resistant detail...
TP53 P177T Nutlin-3 osteosarcoma resistant detail...
Unknown unknown BMS-754807 osteosarcoma not applicable detail...
Unknown unknown Dasatinib osteosarcoma not applicable detail...
NOTCH1 I1680S MRK-003 osteosarcoma sensitive detail...
NOTCH1 E1567K MRK-003 osteosarcoma sensitive detail...
NOTCH1 A1552G MRK-003 osteosarcoma sensitive detail...
NOTCH1 A1552V MRK-003 osteosarcoma sensitive detail...
NOTCH1 A1570G MRK-003 osteosarcoma sensitive detail...
NOTCH1 V1575A MRK-003 osteosarcoma sensitive detail...
NOTCH1 V1599M MRK-003 osteosarcoma sensitive detail...
NOTCH1 A1707T MRK-003 osteosarcoma sensitive detail...
NOTCH1 R1683W MRK-003 osteosarcoma sensitive detail...
NOTCH1 V1676I MRK-003 osteosarcoma sensitive detail...
TP53 mutant RB1 wild-type R547 osteosarcoma sensitive detail...
TP53 wild-type CPUY201112 osteosarcoma sensitive detail...
TP53 loss CPUY201112 osteosarcoma decreased response detail...
Unknown unknown YW3-56 osteosarcoma not applicable detail...
Unknown unknown VCN-01 osteosarcoma not applicable detail...
RB1 mutant VCN-01 osteosarcoma sensitive detail...
Unknown unknown AZD7762 + VE-821 osteosarcoma not applicable detail...
Unknown unknown AZD7762 + Hydroxyurea + VE-821 osteosarcoma not applicable detail...
CBLC dec exp Olaparib osteosarcoma predicted - sensitive detail...
SMO dec exp SANT1 osteosarcoma predicted - sensitive detail...
TP53 wild-type AMG 232 osteosarcoma sensitive detail...
TP53 wild-type AMG 232 + Radiotherapy osteosarcoma sensitive detail...
Unknown unknown WZ4003 osteosarcoma not applicable detail...
Unknown unknown HTH-01-015 osteosarcoma not applicable detail...
Unknown unknown V158411 osteosarcoma not applicable detail...
Unknown unknown Pembrolizumab osteosarcoma not applicable detail...
Unknown unknown Prexasertib osteosarcoma not applicable detail...
Unknown unknown Gemcitabine + Sirolimus osteosarcoma not applicable detail...
TP53 mutant N/A osteosarcoma not applicable detail...
Unknown unknown Capmatinib osteosarcoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00902044 Phase I Fludarabine Cyclophosphamide HER2 sensitized T-cells Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma Recruiting
NCT01241162 Phase I Decitabine Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma Completed
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting
NCT01518413 Phase I Irinotecan + Sorafenib Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Completed
NCT01759303 Phase II Pazopanib Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung Terminated
NCT01956669 Phase II Pazopanib Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Recruiting
NCT02013336 Phase I Cyclophosphamide + MM-398 Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors Recruiting
NCT02048371 Phase II Regorafenib A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas Recruiting
NCT02173093 Phase Ib/II Aldesleukin + GD2Bi-a ATC + Sargramostim Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Recruiting
NCT02304458 Phase Ib/II Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Recruiting
NCT02357810 Phase II Pazopanib + Topotecan Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas Recruiting
NCT02432274 Phase Ib/II Etoposide Lenvatinib Cyclophosphamide Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies Active, not recruiting
NCT02446431 Phase I Cyclophosphamide Bevacizumab Temsirolimus Valproic acid Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence Recruiting
NCT02470091 Phase II Denosumab Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma Active, not recruiting
NCT02487979 Phase II Glembatumumab vedotin Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma Completed
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Recruiting
NCT02815995 Phase II Durvalumab + Tremelimumab Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Active, not recruiting
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Recruiting
NCT02982941 Phase I MGA271 Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Active, not recruiting
NCT03006848 Phase II Avelumab A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma Recruiting
NCT03139331 Phase I Irinotecan + Pazopanib + Temozolomide PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma Recruiting
NCT03190174 Phase Ib/II Nab-Rapamycin + Nivolumab Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting
NCT03282344 Phase II Nivolumab + NKTR-214 A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma Recruiting
NCT03320330 Phase Ib/II VX15/2503 VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Recruiting
NCT03449108 Phase II Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna Iovance Alliance: LN-145 Across Multiple Tumor Types Recruiting
NCT03458728 Phase Ib/II Copanlisib Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Recruiting
NCT03628209 Phase Ib/II Azacitidine + Nivolumab Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Not yet recruiting
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03718091 Phase II VX-970 M6620 (VX-970) in Selected Solid Tumors Recruiting